Could a heart drug tame aneurysms? new study investigates
NCT ID NCT06081153
First seen Jan 11, 2026 · Last updated Jun 02, 2026 · Updated 27 times
Summary
This study tests whether evolocumab, a drug that lowers 'bad' cholesterol, changes the cells in the wall of an abdominal aortic aneurysm. About 44 people scheduled for aneurysm repair will receive either the drug or a placebo before surgery. Researchers will then compare the tissue removed during surgery to see if the drug reduces inflammation or other harmful cell activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL AORTIC ANEURYSM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.